Most-Downgraded StocksMost-DowngradedNYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $66.81 +0.79 (+1.20%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$65.47â–Ľ$67.0450-Day Range$59.70â–Ľ$93.7852-Week Range$58.93â–Ľ$96.12Volume8.17 million shsAverage Volume4.18 million shsMarket Capitalization$40.26 billionP/E Ratio28.80Dividend YieldN/APrice Target$82.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Edwards Lifesciences alerts: Email Address Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.52 Rating ScoreUpside/Downside22.9% Upside$82.10 Price TargetShort InterestHealthy1.07% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.55Based on 12 Articles This WeekInsider TradingSelling Shares$1.32 M Sold Last QuarterProj. Earnings Growth3.33%From $2.70 to $2.79 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.30 out of 5 starsMedical Sector102nd out of 910 stocksSurgical Appliances & Supplies Industry6th out of 18 stocks 3.3 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 11 buy ratings, 13 hold ratings, and no sell ratings.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.07% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 3.93%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 1.4 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Edwards Lifesciences this week, compared to 12 articles on an average week.Search InterestOnly 15 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,321,988.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 3.33% in the coming year, from $2.70 to $2.79 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 28.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 28.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesAugust 21, 2024 | insidertrades.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 1,250 Shares of StockAugust 15, 2024 | insidertrades.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 5,000 Shares of StockSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 6 at 1:45 AM | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 4 at 8:01 AM | finance.yahoo.comWith 85% institutional ownership, Edwards Lifesciences Corporation (NYSE:EW) is a favorite amongst the big gunsSeptember 4 at 3:00 AM | markets.businessinsider.comWells Fargo Sticks to Its Buy Rating for Edwards Lifesciences (EW)September 3, 2024 | finance.yahoo.comEdwards Lifesciences Completes Sale of Critical CareSeptember 1, 2024 | finanznachrichten.deEdwards Lifesciences Corporation: First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards ValvesSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 31, 2024 | businesswire.comCORRECTING and REPLACING First All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards ValvesAugust 31, 2024 | businesswire.comFirst All-Female TAVI Trial Shows Excellent Outcomes for Women Receiving Edwards ValvesAugust 31, 2024 | americanbankingnews.comEdwards Lifesciences Sees Unusually High Options Volume (NYSE:EW)August 30, 2024 | finance.yahoo.comInvestors in Edwards Lifesciences (NYSE:EW) have unfortunately lost 43% over the last three yearsAugust 30, 2024 | benzinga.comEdwards Lifesciences's Options Frenzy: What You Need to KnowAugust 27, 2024 | markets.businessinsider.comBalanced Outlook: Hold Rating on Edwards Lifesciences Amidst Market Uncertainties and Growth PotentialAugust 22, 2024 | markets.businessinsider.comEdwards Lifesciences: A Strong Buy on Market Expansion and Innovative Cardiovascular SolutionsAugust 21, 2024 | nz.finance.yahoo.comEdwards Lifesciences to Present at the 2024 Wells Fargo Healthcare ConferenceAugust 21, 2024 | finance.yahoo.comEstimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)See More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/24/2024Today9/07/2024Next Earnings (Estimated)10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$82.10 High Stock Price Target$106.00 Low Stock Price Target$57.00 Potential Upside/Downside+22.9%Consensus RatingModerate Buy Rating Score (0-4)2.52 Research Coverage25 Analysts Profitability EPS (Most Recent Fiscal Year)$2.32 Trailing P/E Ratio28.80 Forward P/E Ratio24.74 P/E Growth2.92Net Income$1.40 billion Net Margins24.55% Pretax Margin28.68% Return on Equity22.35% Return on Assets16.31% Debt Debt-to-Equity Ratio0.08 Current Ratio3.71 Quick Ratio2.87 Sales & Book Value Annual Sales$6.20 billion Price / Sales6.49 Cash Flow$2.64 per share Price / Cash Flow25.32 Book Value$12.46 per share Price / Book5.36Miscellaneous Outstanding Shares602,600,000Free Float594,826,000Market Cap$40.26 billion OptionableOptionable Beta1.11 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 56)CEO & Director Comp: $2.27MMr. Scott B. Ullem (Age 57)Corporate VP & CFO Comp: $1.35MMr. Donald E. Bobo Jr. (Age 62)Corporate Vice President of Strategy & Corporate Development Comp: $1.27MMr. Larry L. Wood (Age 58)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.49MMr. Andrew M. Dahl (Age 47)Principal Accounting Officer, Senior VP & Corporate Controller Dr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 65)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMs. Christine Z. McCauley (Age 59)Corporate Vice President of Human Resources More ExecutivesKey CompetitorsStrykerNYSE:SYKBoston ScientificNYSE:BSXMedtronicNYSE:MDTBecton, Dickinson and CompanyNYSE:BDXIDEXX LaboratoriesNASDAQ:IDXXView All CompetitorsInsiders & InstitutionsCim LLCBought 2,641 shares on 9/6/2024Ownership: 0.031%Sanctuary Advisors LLCBought 103,173 shares on 9/5/2024Ownership: 0.017%New Century Financial Group LLCBought 912 shares on 8/27/2024Ownership: 0.001%Teachers Retirement System of The State of KentuckySold 5,576 shares on 8/26/2024Ownership: 0.016%Cetera Investment AdvisersSold 5,154 shares on 8/22/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: Edwards Lifesciences reported a 6.7% increase in revenue on a year-over-year basis, indicating growth potential. Analysts expect Edwards Lifesciences to post 2.71 earnings per share for the current year, showing positive earnings outlook. Recent trading activity showed Edwards Lifesciences stock trading up 2.3%, potentially signaling investor confidence. Several hedge funds have increased their holdings in Edwards Lifesciences, suggesting institutional investor interest. Analysts have given a consensus rating of "Moderate Buy" with a target price of $82.10, indicating positive sentiment towards the stock. Cons Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: Multiple analysts have lowered their price targets for Edwards Lifesciences stock, potentially indicating concerns about future performance. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 22, 2024. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com. EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $76.25 on January 1st, 2024. Since then, EW stock has decreased by 12.4% and is now trading at $66.81. View the best growth stocks for 2024 here. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) issued its quarterly earnings results on Wednesday, July, 24th. The medical research company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. The business's revenue was up 6.7% compared to the same quarter last year. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. Does Edwards Lifesciences have any subsidiaries? Edwards Lifesciences subsidiaries include these companies: CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and more. Who are Edwards Lifesciences' major shareholders? Top institutional shareholders of Edwards Lifesciences include Bank of New York Mellon Corp (3.28%), Legal & General Group Plc (0.89%), AustralianSuper Pty Ltd (0.46%) and American Century Companies Inc. (0.35%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Bernard J Zovighian, Kieran Gallahue, Donald E Bobo Jr, Catherine M Szyman, Scott B Ullem, Daveen Chopra, Heisz Leslie Stone, Martha H Marsh, Daniel J Lippis, Robert WA Sellers, Michael A Mussallem, Nicholas J Valeriani and Huimin Wang. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V) and Johnson & Johnson (JNJ). This page (NYSE:EW) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EW Stock Alerts